Lp-PLA2 Activity

What Lp-PLA2 Activity actually measures — the analyte, and the assay

This is an enzyme test wearing a lipid test's clothes. Lp-PLA2 is a 45 kDa calcium-independent phospholipase, the product of the PLA2G7 gene, secreted mostly by macrophages and monocytes. Its other name is platelet-activating factor acetylhydrolase, and the two names describe the same protein doing the same job: cleaving the sn-2 ester of a phospholipid. On an oxidized LDL particle that cut releases lysophosphatidylcholine and an oxidized free fatty acid, which is the step the atherosclerosis argument rests on Zhang 2022.

Roughly 80% of it is riding on LDL, the rest on HDL and Lp(a). That matters more than it sounds: the enzyme has no free circulation of its own, so a fall in LDL particle number lowers the measured value without a single macrophage changing behavior.

Two completely different tests are sold under this one name, and the units are how you tell them apart. A mass assay is an immunoassay: it counts enzyme protein and reports ng/mL. An activity assay is a kinetic reaction: it puts your plasma with a synthetic substrate, watches how fast the ester bond falls apart, and reports nmol/min/mL. One measures how much enzyme is present, the other how much work it does. They are not two calibrations of one number and there is no conversion factor. The version cleared for cardiovascular risk in the United States, and the one this marker's 225 nmol/min/mL line belongs to, is the activity assay.

Genetics treats them as separate traits, which is the strongest evidence they are. A meta-analysis of genome-wide studies across five community-based cohorts looked for loci associated with variation in Lp-PLA2 mass and Lp-PLA2 activity and reported eight, analyzing the two as distinct measurements throughout Grallert 2012.

Even within the activity assay, the instrument used to matter. Results were not interchangeable between analyzers until a recombinant enzyme calibrator was evaluated as a way of harmonizing them Cerelli 2016. A number from 2014 and a number from a different platform today are not automatically the same measurement.

Lp-PLA2 Activity: what changes the blood, and what only changes the reading

What changes the enzyme in your blood — strongest lever first:

1. ApoB particle number. The enzyme is cargo. Cut LDL particles with a statin and the measured activity falls, because you removed the vehicles, not because you calmed the macrophage. This is the single commonest misreading of a repeat result.
2. Your PLA2G7 genotype. Loss-of-function variants exist and are common in some East Asian populations; a carrier can run an activity near the floor of the assay for life with no vascular meaning at all Grallert 2012.
3. Macrophage burden in plaque and elsewhere. The enzyme is secreted by the same cell population that accumulates in an inflamed arterial wall Zhang 2022.
4. Smoking, visceral adiposity and insulin resistance, all of which raise it and all of which also raise apoB — so the effect arrives twice.
5. Sex. Women run lower, which is why the original validation work used sex-specific percentiles rather than one line.
6. Direct enzyme inhibition. Darapladib suppressed activity profoundly and did nothing else useful, which is the subject of this page's limits section White 2014.

What changes only the reading:

1. Which of the two assays was run. A mass result in ng/mL compared against an activity cut-point in nmol/min/mL is not a high or low value; it is a category error. Check the unit on the report before anything else.
2. Which analyzer, and when. Harmonization of activity results between instruments needed a recombinant enzyme calibrator to be evaluated for the purpose Cerelli 2016; results predating that work are not automatically comparable with results after it.
3. Sample handling. An activity assay measures catalysis, so it is sensitive to things a protein immunoassay shrugs off — delayed separation, repeated freeze-thaw, storage temperature.
4. Gross lipemia, which loads the reaction with competing substrate and interferes optically.
5. A changed cut-point. The threshold printed beside the result has been revised commercially; two reports carrying the same activity value can carry different flags.

Reference interval or decision threshold — which kind of number Lp-PLA2 Activity is

225 nmol/min/mL is a decision threshold, and it is not even a physiological one. It is the line the cleared test uses to sort people into higher and lower predicted risk. It was not derived by asking what value keeps an artery healthy; it was derived from where people sat in a distribution and what happened to them afterwards.

The validation work used two lines, not one. The cohort behind the cut-point worked from sex-specific 80th percentiles — around 250 nmol/min/mL for men and 200 for women — and the single marketed number sits between them. A woman at 215 is above her own cohort's 80th percentile and below the printed line. That is a property of the rounding, not of her arteries.

A percentile is a statement about a crowd. The 80th percentile means one person in five was higher. It carries no claim that the other four are safe, and no claim that moving from the 81st percentile to the 79th changes anything.

There is no reference interval here in the usual sense, because the test was never positioned as a health measure with a normal band. It was positioned as a risk stratifier, which is why the report prints one number and a direction rather than a range with two ends.

How you would know your Lp-PLA2 Activity was wrong — and when to redraw

The clock belongs to the particle, not the enzyme. An LDL particle circulates for roughly 2 to 4 days before clearance, and the enzyme on it goes with it. So a real change in Lp-PLA2 activity follows a real change in apoB within weeks, and there is no biological reason to redraw sooner. 6 to 12 weeks after a lipid intervention has reached steady state is the honest interval.

Conditions the second draw has to match: the same assay type — activity for activity — the same laboratory and platform Cerelli 2016, comparable fasting state, and no acute illness in the preceding fortnight.

What would have to change for the second number to mean anything. Lp-PLA2 alone cannot tell you which of two things happened, and the companion test decides it:

• Draw an ApoB beside it every time. If activity fell and apoB fell in proportion, you removed carriers. If activity fell and apoB did not move, something changed about the enzyme itself. Those are different results and the Lp-PLA2 number cannot separate them.
• An hs-CRP tests the inflammation story. A falling Lp-PLA2 with a static hs-CRP is not an anti-inflammatory response.
• An Lp(a) explains a stubborn value, since Lp(a) carries the enzyme too and does not respond to the levers that move LDL.
• A floor-level result should prompt a question, not a celebration. An activity near the bottom of the assay in someone with unremarkable lipids is more likely to be genotype than achievement Grallert 2012.

What Lp-PLA2 Activity cannot tell you

It cannot tell you that lowering it will help you, and the largest test of that idea said the opposite. Darapladib is a direct Lp-PLA2 inhibitor. In 15,828 patients with stable coronary disease followed a median 3.7 years, the primary endpoint occurred in 769 of 7,924 (9.7%) on darapladib and 819 of 7,904 (10.4%) on placebo — hazard ratio 0.94, 95% CI 0.85 to 1.03, P = 0.20 White 2014. A later pharmacogenetic meta-analysis pooled the baseline risk factors, pharmacodynamics, efficacy and tolerability of two large outcome trials of the drug Yeo 2017. Suppressing the enzyme did not deliver the events benefit the marker predicted. That is the definition of a risk marker rather than a causal target, and it is the most important sentence on this page.

It cannot separate itself from your LDL. Because most of the enzyme rides on apoB particles, a large part of any Lp-PLA2 result is a restatement of information ApoB already gave you. The independent signal is the part that is left after that, and it is smaller than the test's marketing implies.

It cannot localize anything. There is no plaque, no artery and no side of the body in this number. A high value does not indicate where; imaging does that and blood does not.

It cannot be compared with somebody else's result unless both came from the same kind of assay on a harmonized platform Cerelli 2016, which is exactly the comparison people make in forums and comment sections.

The wrong inference readers actually draw is that a falling Lp-PLA2 on a statin proves the statin calmed vascular inflammation. It proves there are fewer LDL particles to carry enzyme. Whether the wall quieted down is a question hs-CRP and imaging answer, not this one.

Sources read for these sections

• White HD, et al. Darapladib for preventing ischemic events in stable coronary heart disease. New England Journal of Medicine 2014 · PMID 24678955
• Yeo A, et al. Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. PLoS One 2017 · PMID 28753643
• Cerelli MJ, et al. Evaluation of recombinant enzyme calibration to harmonize lipoprotein-associated phospholipase A2 activity results between instruments. Clinical Biochemistry 2016 · PMID 26656641
• Grallert H, et al. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. European Heart Journal 2012 · PMID 22003152
• Zhang S, et al. Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A2 in Ischemic Stroke. Cardiovascular Therapeutics 2022 · PMID 36313479